InVivo Therapeutics: Liquidation Process Reaches Final Stages

The dissolution of InVivo Therapeutics Holdings is now in its concluding phase. The company’s operations, along with all its research and development initiatives, have ceased. Current oversight has been transferred to a liquidation trust, with market attention focused solely on the administrative winding down of remaining assets and the resolution of outstanding liabilities.

Remaining Assets and Shareholder Prospects

Any residual value for equity holders will only be determined following the final settlement of all estate accounts. The primary driver for remaining share value is the ultimate accounting of the trust’s assets. With the official termination of clinical trials and the development of its core polymer technology, no further operational updates regarding medical progress or product launches are anticipated.

The timeline for any potential distribution of funds to shareholders is contingent upon the complete coverage of administrative costs and the satisfaction of priority creditor claims. The appointed trustee holds responsibility for managing the remaining assets and overseeing any final disbursements.

Should investors sell immediately? Or is it worth buying InVivo Therapeutics Holdings?

Intellectual Property in Limbo

A technical component of the wind-down involves the company’s existing license agreements for its bioresorbable polymer technology. These contracts with academic and research institutions remain in effect, as scheduled, until 2027 or until the associated patents expire. While InVivo Therapeutics no longer utilizes these licenses for active production, they constitute a portion of the entity’s remaining assets.

Research Continues Elsewhere

Although InVivo’s specific programs have been discontinued, the field of spinal cord injury research remains active. Other clinical-stage companies and academic centers continue to advance work in this area. The market for neuro-spinal treatments is evolving, with a growing emphasis on newer technology platforms and adapted regulatory strategies.

The focus for InVivo Therapeutics is firmly fixed on the legal and financial closure of the corporation. The fate of its shares depends entirely on the final balance sheet of the liquidation trust, as no further business initiatives from this entity are expected.